A study was conducted in Denmark to assess the awareness of the teratogenic risks associated with oral retinoids and the adherence to pregnancy prevention programs (PPP) among healthcare providers and patients.
Surveys were distributed to dermatologists, general practitioners, pharmacists, and women of childbearing age using oral retinoids, revealing high awareness levels of teratogenicity (95-100%) across the groups.
Despite this awareness, there was inconsistent adherence to PPP measures, indicating a need for improved accessibility and encouragement of certain safety practices, especially those requiring patient signatures.